Table 3 Univariate Analyses

 < 4

ref

^a

^a

 ≥ 4

1.24 (1.00–1.53)

 < 65

ref

ref

ref

 ≥ 65

1.34 (1.11–1.63)

1.77 (1.40–2.22)

0.72 (0.53–0.98(

 0

ref

ref

ref

 1

1.53 (1.22–1.93)

1.81 (1.36–2.39)

0.72 (0.52–1.00)

 2+

2.06 (1.37–3.10)

3.37 (2.17–5.25)

0.19 (0.06–0.63)

 Unknown

1.75 (1.33–2.31

2.04 (1.47–2.83)

0.79 (0.51–1.23)

 < 5 cm

ref

ref

^a

 5–10 cm

0.92 (0.74–1.16)

0.90 (0.69–1.18)

 > 10 cm

0.79 (0.59–1.05)

0.72 (0.51–1.02)

 Unknown

1.49 (1.02–2.15)

1.52 (1.00–2.33)

 < 5

ref

ref

ref

 ≥ 5

1.71 (1.39–2.11)

1.83 (1.43–2.34)

0.37 (0.26–0.54)

 Unknown

1.63 (1.21–2.19)

1.49 (1.04–2.13)

0.69 (0.43–1.12)

 II

ref

ref

ref

 III

1.21 (0.97–1.52)

1.07 (0.82–1.39)

0.66 (0.49–0.91)

 Unknown

3.35 (1.75–6.43)

4.14 (2.07–8.26)

0.25 (0.03–1.92)

 Hemoglobin^b

0.99 (0.99–1.00)

0.99 (0.98–1.00)

1.01 (1.00–1.02)

 5-fluorouracil

ref

ref

^a

 Capecitabine

1.30 (1.06–1.60)

1.27 (0.99–1.63)

 Raltitrexed

0.56 (0.18–1.75)

0.52 (0.13–2.08)

 Unknown

2.95 (1.82–4.76)

3.28 (1.90–5.65)

 Not received

ref

ref

N/A

 Received

0.63 (0.51–0.77)

0.45 (0.35–0.56)

N/A

 Alberta

ref

ref

ref

 British Columbia

1.50 (1.19–1.90)

1.34 (1.02–1.75)

0.56 (0.37–0.86)

 Ontario

0.65 (0.51–0.84)

0.47 (0.35–0.64)

0.83 (0.60–1.16)